ID: ALA2063395

Max Phase: Preclinical

Molecular Formula: C26H37N5O4

Molecular Weight: 483.61

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCC[C@@H]1NC(=O)[C@H](C)NC(=O)C[C@H](CC(C)C)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O

Standard InChI:  InChI=1S/C26H37N5O4/c1-5-8-21-25(34)31-22(12-17-14-27-20-10-7-6-9-19(17)20)26(35)29-18(11-15(2)3)13-23(32)28-16(4)24(33)30-21/h6-7,9-10,14-16,18,21-22,27H,5,8,11-13H2,1-4H3,(H,28,32)(H,29,35)(H,30,33)(H,31,34)/t16-,18-,21-,22-/m0/s1

Standard InChI Key:  LHUGWXWDPVKZOS-DBXVSBKESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 483.61

Molecular Weight (Monoisotopic): 483.2846

AlogP: 1.92

#Rotatable Bonds: 6

Polar Surface Area: 132.19

Molecular Species: NEUTRAL

HBA: 4

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.06

CX Basic pKa:

CX LogP: 1.92

CX LogD: 1.91

Aromatic Rings: 2

Heavy Atoms: 35

QED Weighted: 0.43

Np Likeness Score: 1.07

References

1. Vickers CJ, Olsen CA, Leman LJ, Ghadiri MR..  (2012)  Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.,  3  (6): [PMID:24900500] [10.1021/ml300081u]

2. Lai JI, Leman LJ, Ku S, Vickers CJ, Olsen CA, Montero A, Ghadiri MR, Gottesfeld JM..  (2017)  Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.,  27  (15): [PMID:28648462] [10.1016/j.bmcl.2017.06.027]

Source

Source(1):

• Scientific Literature